Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we sprint through hypercalcemia—recognize fast, rehydrate hard, block bone resorption, and fix the cause.
We open with the do-firsts: confirm true hypercalcemia (ionized preferred; corrected total if needed), grab PTH → PTHrP/25-OH D/1,25-(OH)₂D, BMP/Phos/Mg, ECG for shortened QT, and scan meds (thiazides, lithium, vit D/Ca, vit A). Severity matters and speed kills: mild <12 mg/dL; moderate 12–14; severe ≥14 mg/dL or any altered mentation.
Etiology at a glance:• Malignancy (most inpatient, most severe): PTHrP, osteolytic mets, ↑calcitriol (lymphoma), rarely ectopic PTH.• Primary hyperparathyroidism (adenoma > hyperplasia > carcinoma).• Others: granulomatous disease, meds, milk-alkali, thyrotoxicosis, adrenal insufficiency, immobilization, toxins.
Diagnosis pearls:• Ionized Ca beats “corrected” when albumin or pH is off.• Low PTH → hunt malignancy/Vit D; high/“inappropriately normal” PTH → PHPT/FHH workup (24-h urine Ca).• Symptoms scale with level + rate of rise: confusion/coma, polyuria/AKI, constipation/N/V, arrhythmias.
Treatment—build the acute backbone:• Volume first: isotonic saline 200–300 mL/h (bolus if shocked) → target UOP 100–150 mL/h; watch for fluid overload (elderly/HFpEF/CKD).• Only after euvolemia, consider loop diuretic for overload.• Antiresorptives early (effect in 24–72 h):– Zoledronic acid 4 mg IV over ~15 min (renal dose-adjust/avoid if severe CKD).– Pamidronate 60–90 mg IV over ~2 h as alternative.– Denosumab 120 mg SQ when refractory or renal impairment—not renally cleared and often first-line in HCM with CKD.• Calcitonin 4–8 IU/kg SQ/IM q8–12h for rapid but short-lived drop (tachyphylaxis by 48–72 h).• Glucocorticoids (e.g., prednisone 40–60 mg/d x ~10 d) for vitamin D–mediated causes (granulomatous dz, lymphoma).• Cinacalcet for parathyroid carcinoma or select refractory PTH-driven cases.• Dialysis (low/zero-Ca bath) for life-threatening hypercalcemia with renal failure or medical therapy failure.
Definitive moves:• Treat the cancer (chemo, radiation, anti-myeloma, debulk).• Parathyroidectomy cures PHPT when criteria met; otherwise optimize hydration, stop offenders, and plan surgery.
Monitoring that sticks:• Strict I/O, weights, vitals; telemetry if severe.• BMP/Ca/Mg/Phos q6–12h acutely; check Ca daily once stable.• Renal dosing for bisphosphonates; expect nadir at 48–72 h—bridge with fluids ± calcitonin.• Avoid Ca, vit D, and thiazides until normalized.
Pitfalls you don’t want to meet:• Skipping fluids and reaching for diuretics too early.• Bisphosphonate in advanced CKD without considering denosumab.• Chasing numbers with calcitonin beyond 72 h.• Missing vitamin D–mediated hypercalcemia (no steroids given).• Treating “corrected Ca” when ionized is normal.
We close with the system moves: a hypercalcemia bundle that (1) defaults to ionized Ca + PTH upfront; (2) auto-hydrates to euvolemia; (3) fires antiresorptive order set (zoledronate/pamidronate or denosumab in CKD); (4) adds calcitonin for severe/symptomatic bridging; (5) routes vitamin D–mediated to a steroid track; (6) screens meds & stops offenders; (7) flags oncology/ENT-endo for definitive therapy; (8) hard-wires monitoring (labs, ECG, fluid balance).
Hydrate, block bone, bridge smartly, and fix the driver—fast.

In this episode of Hospital Medicine Unplugged, we blitz through hypocalcemia—measure ionized calcium, treat symptoms now, fix the cause, and avoid reflex over-correction in the ICU.
We open with the do-firsts: confirm with ionized Ca (total Ca lies in hypoalbuminemia), check Mg/Phos/Cr, PTH, 25-OH D, ECG for QT prolongation, and scan the story (neck surgery, CKD, vitamin D deficiency, sepsis, pancreatitis, meds, massive transfusion).
Call the problem when ionized Ca <1.1 mmol/L (or total Ca <8 mg/dL—use with caution). Symptoms span paresthesias → tetany → seizures, laryngospasm, bronchospasm → HF/arrhythmias. Hypomagnesemia can both cause and perpetuate hypocalcemia—correct it.
Etiology buckets you’ll meet fast:• Low/ineffective PTH: post-op hypoparathyroidism, autoimmune, infiltrative, severe hypoMg.• PTH resistance / CaSR/GNAS disorders.• Vitamin D deficiency or low 1,25-(OH)₂D (malabsorption, CKD, meds).• Chelation/precipitation: citrate from massive transfusion, pancreatitis, TLS, rhabdo.• Critical illness: impaired PTH action & vitamin D metabolism.
Who needs admission/telemetry right now? Severe symptoms, ionized Ca <0.9 mmol/L, QTc changes, post-thyroid/parathyroid surgery with falling Ca, massive transfusion, pancreatitis/sepsis with instability.
Treatment—build the acute backbone:• IV calcium for severe/symptomatic: 10–20 mL of 10% calcium gluconate (≈93 mg elemental Ca per 10 mL) over 10–15 min with ECG, then infuse to target low-normal ionized Ca (e.g., ~1.1–1.2 mmol/L).• Prefer gluconate peripherally; chloride is central-line only (tissue necrosis risk).• Replete Mg (e.g., MgSO₄ 1–2 g IV; more if renally appropriate) before/with calcium.• Treat the trigger: stop causative meds, give vitamin D/calcitriol if deficient or hypoparathyroid, manage sepsis/pancreatitis, and in hemorrhage dose calcium during MTP.
Maintenance & chronic plays:• Oral calcium (carbonate/citrate in divided doses) + vitamin D; add calcitriol when PTH is low/ineffective.• Target low-normal Ca to limit hypercalciuria/nephrocalcinosis; consider thiazide if urinary Ca high.• rhPTH/long-acting PTH analogues for select hypoparathyroid patients to cut Ca/calcitriol burden—cost/safety/selection matter.
ICU reality check:• Hypocalcemia is common and tracks severity of illness. Routine IV Ca for asymptomatic ICU patients (esp. sepsis) hasn’t shown outcome benefit and may be harmful—individualize. Failure to normalize ionized Ca over the first few ICU days correlates with worse outcomes, but causality is uncertain.
Special situations you’ll see:• Post-thyroidectomy: early Ca + calcitriol, PTH-guided protocols, monitor Mg; escalate to IV if symptomatic or Ca <~7–8 mg/dL.• CKD/CKD-MBD: tolerate mild asymptomatic hypocalcemia; avoid positive Ca balance/vascular calcification; control phosphate; use active vitamin D selectively.• Pancreatitis: replace only if symptomatic/severe; no routine calcium to chase numbers.• Massive transfusion: citrate chelation—aim ionized Ca >1.0–1.2 mmol/L with protocolized Ca (often 1 g gluconate early and intermittently).
Monitoring that sticks:• During IV therapy: ionized Ca q1–2h while titrating, then q4–6h; continuous ECG.• Check Mg/Phos and correct; reassess Ca needs after fixing Mg.• Chronic: Ca/Phos/Mg/Cr q3–6 mo; 24-h urine Ca (goal <4 mg/kg/day); periodic renal imaging if hypercalciuria or rising Cr.
Pitfalls you don’t want to meet:• Treating numbers, not patients in the ICU.• Forgetting magnesium—you’ll chase Ca forever.• Pushing CaCl peripherally—extravasation disaster.• Overshooting Ca in CKD → vascular calcification.• Skipping vitamin D in low/ineffective PTH states.
We close with the system moves: a hypocalcemia bundle that (1) defaults to ionized Ca + Mg/Phos/PTH/25-OH D + ECG; (2) triages to IV Ca + Mg for symptomatic/severe; (3) targets low-normal ionized Ca, not “high-normal”; (4) hard-wires Mg repletion; (5) routes special scenarios (post-op, CKD, MTP, pancreatitis) to tailored pathways; (6) sets outpatient labs/urine Ca to prevent stones and nephrocalcinosis.
Fast recognition, ionized-first confirmation, symptom-driven IV calcium, relentless Mg correction, and etiology-specific fixes—treat wisely, not reflexively.

In this episode of Hospital Medicine Unplugged, we power through hepatic encephalopathy—find the trigger fast, start lactulose early, layer rifaximin when needed, and protect the airway and the brain.
We open with the do-firsts: stabilize ABCs, grade mental status (West Haven), check glucose/electrolytes, and hunt precipitants—infection (incl. SBP), GI bleed, AKI/dehydration, constipation, hyponatremia/hypokalemia, sedatives/opioids, and post-TIPS/large shunts. Image the brain only if the story doesn’t fit or focal signs appear. Treat while you evaluate—don’t wait for ammonia levels to “confirm.”
Core therapy—nonabsorbable disaccharides (lactulose) are first-line:• Start orally/NG or as retention enema; titrate to 2–3 soft stools/day (avoid diarrhea/dehydration).• Individualize care—cirrhotics dominate the evidence base, so recommendations are conditional but consistent.• PEG is a reasonable alternative for rapid catharsis in ICU (e.g., 4 L over ~4 h), but the volume raises aspiration risk in advanced grades—use with caution.
Adjuncts that change outcomes:• Rifaximin 550 mg BID with lactulose for recurrent/persistent HE—fewer recurrences and hospitalizations, better maintenance.• Glycerol phenylbutyrate (GPB) lowers ammonia via an alternate pathway; cuts events but watch cost and renal clearance (be cautious in AKI).• Neomycin/metronidazole—lower-tier options due to toxicity/limited efficacy.
Things that may help—but won’t save the day:• Flumazenil can transiently improve mentation (suspected benzo effect) but no mortality benefit and seizure risk—short, monitored trials only.• Probiotics may reduce incident overt HE, no mortality signal.• Zinc can improve psychometrics, no effect on recurrence/QoL.
Supportive moves that matter:• Protein restriction is out—maintain normal protein intake to prevent sarcopenia; consider late-evening protein and BCAAs for select patients.• Correct hyponatremia/hypokalemia, optimize volume, target infection early.• Choose sedatives wisely (short-acting, especially if intubated).• Grade 3–4 HE or GCS <8 → ICU, airway protection, and close neuro checks.
When HE won’t quit (refractory track):• Re-interrogate for hidden precipitants and large portosystemic shunts—consider embolization if liver function allows.• Discuss advanced ammonia-lowering options (e.g., CRRT/albumin dialysis in select scenarios) with hepatology/ICU.• Liver transplantation is the only definitive therapy for end-stage disease or recurrent HE despite optimized care—refer early.
Monitoring & discharge that stick:• Trend clinical grade and function, not ammonia numbers.• Watch for treatment adverse effects (diarrhea, dehydration, electrolyte shifts).• Maintain lactulose + rifaximin after resolution for secondary prevention.• Build a recurrence-proof plan: medication adherence, infection vigilance, bowel regimen, driving/falls counseling, nutrition follow-up, and tight outpatient touchpoints.
System moves you can implement tomorrow: a bedside HE bundle that (1) auto-screens precipitants; (2) starts lactulose now with NG/enema backups; (3) flags PEG as a situational ICU tool; (4) defaults to rifaximin add-on for recurrent/persistent cases; (5) normalizes protein and corrects electrolytes; (6) escalates refractory cases to shunt embolization/transplant eval; (7) hard-wires education + follow-up into discharge.
Bottom line: Treat the trigger, move early with lactulose, add rifaximin to prevent the bounce-back, nourish rather than restrict, and escalate thoughtfully—ICU when severe, transplant when needed.

In this episode of Hospital Medicine Unplugged, we tackle pneumothorax in the inpatient world—stabilize first, size it right, choose the least invasive path that’s safe, and never miss tension physiology.
We open with the first five minutes: is the patient stable? Check vitals and work of breathing, then confirm with imaging—CXR first-line, POCUS for speed/supine patients, CT when the picture’s hazy or occult. If tension is suspected, treat now—don’t wait for imaging. Tube thoracostomy is definitive.
Classification that actually changes management: primary spontaneous (PSP), secondary spontaneous (SSP), iatrogenic, traumatic, and tension. But modern imaging blurs PSP vs SSP—let size + symptoms drive decisions, with special caution in SSP and ventilated patients.
Conservative lane (when it’s safe):• Stable PSP, minimal symptoms → observation ± oxygen. Recent trials show noninferior 8-week re-expansion, fewer procedures, shorter LOS. Selection matters: reliable follow-up, no significant compromise.• Iatrogenic, small, asymptomatic → observe and re-image.
Interventional lane (when to act):• Significant symptoms, large size, instability, or failed observation.• Needle aspiration can succeed in ~70% of stable PSP and may avoid admission; recurrence similar to tubes but shorter stays.• If aspiration fails/contraindicated or SSP present → small-bore chest tube (≤14F) preferred; attach to water seal/Heimlich valve, add suction if no re-expansion.• Ambulatory one-way valves are emerging for select stable patients.
Special situations you can’t miss:• Trauma: intervene by size thresholds (e.g., >20% on CXR or >35 mm on CT) and clinical status. Unstable or ventilated? Tube now. Consider antibiotics before placement and warm-saline irrigation to reduce re-interventions.• ICU/ventilated: low threshold to drain occult PTX. Persistent air leak or non-expansion → early surgery (day 3–5).• Tension: needle decompression → definitive tube, monitor for re-expansion edema.
Complications & tech that help:• Persistent air leak, non-expansion, recurrence → surgical consult.• Digital air-leak monitoring can shorten tube time and LOS; adoption varies.• Invasive strategies carry more pain, infection, device issues—pick the lightest touch that works.
Recurrence & prevention plays:• SSP has higher recurrence and morbidity—lean earlier to recurrence prevention.• Options: VATS bullectomy + mechanical/talc pleurodesis (lowest recurrence), or chemical pleurodesis via tube if not surgical.• Smoking cessation is non-negotiable.
What we still don’t know (and what we discuss):• Optimal SSP pathways, standardized size definitions, and who truly benefits from ambulatory devices/outpatient care.• How to best integrate digital air-leak monitoring into everyday practice.
We close with a simple ward-ready pathway:
Stability check → treat tension immediately.
Image smart (CXR → POCUS → CT when needed).
Stable PSP, low symptoms? Consider conservative care with clear follow-up.
If symptoms/size/SSP: aspiration → small-bore tube → suction if needed.
Trauma or vents: tube early; involve surgery by day 3–5 if leak persists.
Plan recurrence prevention before discharge (especially SSP).
Educate, mobilize smoking cessation, and schedule objective follow-up imaging.
Bottom line: Prioritize stability, use size + symptoms over labels, prefer small-bore and conservative strategies when safe, move fast for tension/vented patients, and prevent the next hit—especially in SSP.

In this episode of Hospital Medicine Unplugged, we tackle hypernatremia—spot it early, fix the water–salt mismatch, and keep brains safe while you correct.
We open with who’s at risk and why it matters: older adults, nursing-home residents, cognitively impaired, immobilized, and ICU patients (prevalence up to 27%). Consequences aren’t subtle: delirium, falls, functional decline, and in-/post-discharge mortality often >30–40% in severe cases—and many survivors lose independence. Iatrogenesis is common.
Diagnosis done fast and right:• History that hunts intake/losses/meds (diuretics, hypertonic infusions, tube feeds).• Exam for volume status and mental status.• Labs: serum/urine electrolytes + osmolality; urine Osm to sort renal vs. extrarenal water loss.• Calculate free-water deficit (use TBW × [(serum Na/desired Na) − 1]) to plan replacement.• Think mechanisms: thirst/AVP/renal concentrating—when any fail, Na rises.
Management—build a safe correction plan:• Treat the cause first (stop sodium loads/over-diuresis, manage DI, address GI losses).• If in shock, restore intravascular volume with isotonic saline, then switch to hypotonic therapy.• Replace with enteral water when possible; otherwise D5W or 0.45% NaCl, tailored to deficit, volume status, and ongoing losses.• Monitoring is non-negotiable: check Na q2–4h during active correction, track I/O, weight, neuro checks.• Correction targets: chronic/unknown duration ≤10–12 mmol/L/day (≤0.5 mmol/L/h); in clearly acute/admission-related severe hypernatremia, faster correction up to ~1 mmol/L/h can be reasonable and has not shown major neuro complications—individualize by chronicity, severity, and comorbids.• ICU myth-busting: with electrolyte-free water, meaningful ECFV expansion is uncommon; persistent hypernatremia tracks with worse outcomes.
Complications you’re preventing:• Cerebral edema from overly rapid correction in chronic cases; intracerebral bleeding with abrupt rises.• Delirium, falls, functional decline, and mortality if under-recognized or undertreated.• Iatrogenic harm from sodium-rich fluids and missed free-water needs (especially with feeds).
Prevention plays that work:• Protocolize: automatic free-water flushes with enteral nutrition, standardized hypernatremia order sets, and medication review for hidden sodium.• Education + dashboards to flag rising Na and prompt early intervention.• Reassess if Na isn’t improving by hospital day 3.
We close with the system bundle: (1) Screen high-risk patients daily; (2) confirm true hypernatremia and classify volume status; (3) calculate deficit + set a correction rate matched to chronicity; (4) default to enteral water/D5W or 0.45% with q2–4h Na checks; (5) avoid/stop sodium loads and fix losses; (6) use isotonic saline only for shock then pivot; (7) document and trend neuro status, I/O, CR/BUN; (8) embed prevention in tube-feed and NPO workflows.
Fast recognition, meticulous monitoring, and cause-directed, rate-aware correction—that’s how you turn a lethal, often iatrogenic problem into a controlled win.

In this episode of Hospital Medicine Unplugged, we dive into massive hemoptysis—stabilize fast, protect the airway, localize the bleed, and stop it for good.
We start with the killer reality: mortality isn’t from bleeding out, it’s from asphyxiation. Even small volumes can flood the airways and crash oxygenation. Massive hemoptysis = ≥200 mL/24 h or any volume causing respiratory/hemodynamic compromise.
Immediate moves:• Airway first—large-bore cuffed ETT, consider selective mainstem if bleeding side known.• Positioning: bleeding lung down.• Oxygen + resuscitation, reverse coagulopathy, crossmatch blood.• Call the multidisciplinary team early—pulmonology, IR, thoracic surgery.
Diagnostics after stabilization:• CXR to check tube, look for opacification (≥2 lung zones = ↑mortality).• CTA chest = gold standard for localizing bleed and guiding embolization.• Bronchoscopy (rigid or flexible) in unstable patients—suction clots, tamponade, balloon occlusion, topical hemostatics.
Definitive hemorrhage control:• Bronchial artery embolization (BAE) = first-line: >85% immediate success, lower morbidity/mortality than surgery, recurrence 10–20%. Risk: rare spinal cord ischemia.• Bronchoscopy interventions: tamponade, thermal therapies, topical vasoconstrictors—best for central bleeds or temporization.• Surgery (lobectomy/pneumonectomy): reserved for refractory/recurrent bleeding or surgically correctable pathology; high risk if emergent, better outcomes when delayed after stabilization.
Adjunctive therapies:• Tranexamic acid (TXA): nebulized (500 mg TID) shows promise in RCTs for moderate/non-massive hemoptysis; IV or nebulized use in massive cases = temporizing, not definitive.• Topical iced saline, epinephrine, hemostatic mesh during bronchoscopy.• Supportive: O₂, hemodynamic support, transfusion, immunosuppression for DAH, infection control.
Monitoring & complications:• ICU-level monitoring—continuous SpO₂, ECG, serial Hgb/coags, suction output.• Watch for recurrence (esp. early post-BAE), aspiration, airway trauma, infection, embolization complications, surgical morbidity.
Prognosis:• Mortality 20–38%, higher in malignancy (up to 100%).• BAE improves survival vs emergent surgery, but recurrence remains common.• Long-term outcomes hinge on etiology (bronchiectasis, TB, malignancy).
Bottom line: Airway, positioning, and multidisciplinary activation save lives. CTA + BAE is the definitive play, bronchoscopy stabilizes, surgery is last resort. Adjuncts buy time, not cure. Act fast, escalate smart, and never underestimate the asphyxiation risk.

In this episode of Hospital Medicine Unplugged, we break down hypertensive crisis—separating urgency from emergency, tailoring the pace of reduction, and choosing the right IV agent for the right patient.
We open with the definitions:• Hypertensive emergency = BP >180/120 with acute target-organ damage (brain, arteries, retina, kidneys, heart). These patients need monitored ICU care and IV titratable agents.• Hypertensive urgency = same severe BP, but no acute injury—safe to manage with oral meds + outpatient follow-up, not IV drips or rapid lowering.
Why it matters: rapid BP reduction in urgency risks AKI, cerebral hypoperfusion, and longer stays—no benefit shown. In emergency, uncontrolled pressure fuels stroke, MI, aortic dissection, renal failure—time-sensitive management prevents irreversible injury.
Management pearls:• Emergency: drop no more than 25% in 1 hour, then target 160/100–110 over 2–6 h, then gradual normalization over 24–48 h. Exception: aortic dissection → SBP ≤120 + HR <60 within 20 min.• Urgency: optimize oral therapy, address adherence, stressors, NSAID/cocaine use, pain. No need for hospitalization unless other issues.
IV agent playbook (scenario-driven):• Aortic dissection: Esmolol/labetalol first (control HR), then add vasodilator (nicardipine, clevidipine).• Acute coronary syndrome: Nitroglycerin, beta-blockers, nicardipine. Avoid nitrates if recent PDE-5 use.• Pulmonary edema: Clevidipine, nitroglycerin, nitroprusside (avoid beta-blockers).• Acute kidney injury: Clevidipine, nicardipine, fenoldopam (renal-protective).• Stroke:– Ischemic (if thrombolysis planned): get <185/110 before lysis.– Intracerebral hemorrhage: SBP to 140–150 within 1 h.– Avoid hydralazine—unpredictable and risky.• Preeclampsia/eclampsia: Hydralazine, labetalol, nicardipine, oral nifedipine. No ACEi/ARB/renin inhibitors. Always add magnesium sulfate for seizure prophylaxis.• Catecholamine excess (pheo, cocaine, amphetamines): Phentolamine, nicardipine, clevidipine—avoid β-blocker monotherapy.
Monitoring that sticks:• ICU/stepdown with arterial line for emergencies; BP q5–15 min, continuous ECG, urine output, neuro checks.• Labs: renal function, troponin, UA, electrolytes. Imaging: CT/MRI brain, CXR, echo, CTA aorta as indicated.• Watch for overshoot hypotension—if SBP <100–120, hold drips immediately.
Prognosis reality check:• Emergency: in-hospital mortality up to 10%, 1-year CV morbidity/mortality 20–30%. Prognosis varies—aortic dissection mortality 1–2% per hour untreated; ICH 30-day mortality >40%; preeclampsia/eclampsia—maternal/fetal outcomes hinge on rapid BP + seizure control.• Urgency: short-term risk low—prognosis tied to long-term BP control, not immediate crisis.
Bottom line: check for organ damage, choose the right lane (urgency vs emergency), titrate carefully, tailor the IV agent to the scenario, and don’t overtreat stable patients. That’s how you save lives and avoid iatrogenic harm.

In this episode of Hospital Medicine Unplugged, we tackle enteral nutrition (EN) in hospitalized patients—screen early, start within 24–48 h when indicated, tailor the route and formula, and prevent complications like refeeding syndrome.
We start with the definitions and routes:• Short-term (<4–6 weeks): NG, NJ, or nasoduodenal tubes.• Long-term (>4–6 weeks): PEG or jejunostomy, with endoscopic placement safest.Gastric access is standard; switch to postpyloric if aspiration risk or intolerance.
When to use EN? If the patient cannot meet needs orally and has no contraindication (e.g., obstruction, uncontrolled shock, ischemia, high-output fistula, massive GI bleed). EN beats PN—lower infections, cost, and complications. Indications include critical illness, dysphagia, neuro disease, GI/liver disease, cancer, COPD, CKD.
Timing:• ICU: start within 24–48 h if no contraindications, even with vasopressors if stable. Use trophic feeds early, advance cautiously.• Non-ICU: start if intake will be <60–75% of needs for ≥7 days.• Post-op: resume within 24 h if possible.
Dosing & advancement:• Energy: 25–30 kcal/kg/day (restrict to ≤70% of goal in first 3–7 days in ICU).• Protein: 0.8 g/kg/day early → 1.2–2.0 g/kg/day in rehab; higher for burns/obesity.• Advance slowly in refeeding risk; always correct electrolytes first.
Formula selection:• Standard polymeric = first-line.• Elemental/semi-elemental for malabsorption/short bowel.• Disease-specific (renal, diabetes) only if clear benefit.• Immune-modulating (arginine + fish oil) for post-op surgical ICU, not routine.
Administration methods:• Continuous pump feeds = safest in ICU.• Intermittent/bolus for stable ward patients.• Volume-based feeding protocols beat rate-based at meeting goals.• Skip routine gastric residuals—hold only if >500 mL + symptoms.• Prevent aspiration with HOB 30–45°, prokinetics, postpyloric feeding if needed.
Complications:• Metabolic: hyperglycemia, electrolyte shifts, refeeding syndrome (watch Phos, K, Mg; give thiamine 100 mg x 7–10 days).• GI: diarrhea (meds, infections, formula), constipation, vomiting—adjust meds, formulas, or route.• Infectious: aspiration pneumonia (prevent with positioning + tube strategy).• Mechanical: clogging (flush regularly, avoid unnecessary residual checks), displacement (secure tubes).
Special situations:• Refeeding syndrome: start low (≤500 kcal/day), advance over 4–7 days, supplement electrolytes + thiamine, monitor daily.• Critical illness: restrict energy early, focus on protein, tolerate partial underfeeding in acute phase.• ICU protocols: nurse-driven, volume-based, with multidisciplinary oversight.
Bottom line: EN early, unless contraindicated. Screen for malnutrition, start low and advance as tolerated, choose standard formulas first, protocolize administration, monitor closely, and prevent refeeding and aspiration. That’s how you fuel recovery safely and improve outcomes.